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Key messages
What is already known about this subject?
 ► Considering the hypothesis that COVID-19 
in its worst manifestations resembles a 
secondary, viral- driven haemophagocitic 
lymphohistiocytosis syndrome, a rationale for 
the use of antirheumatic drugs that are used for 
autoinflammatory disease have been placed in 
the algorithm of treatment.
What does this study add?
 ► Based on anti- inflammatory and potential 
antiviral properties, colchicine was administered 
to hospitalised patients with COVID-19 
pneumonia and acute respiratory distress 
syndrome (ARDS).
 ► The survival rate of patients treated with 
colchicine was significantly higher as compared 
with that of patients treated with standard of 
care only (84.2% vs 63.6%).
How might this impact on clinical practice or 
future developments?
 ► This proof- of- concept study supports the 
rationale of testing colchicine in clinical trials 
for the treatment of COVID-19 pneumonia with 
ARDS.
AbsTrACT
Objectives The outbreak of COViD-19 posed the 
issue of urgently identifying treatment strategies. 
Colchicine was considered for this purpose based on 
well- recognised anti- inflammatory effects and potential 
antiviral properties. in the present study, colchicine was 
proposed to patients with COViD-19, and its effects 
compared with ’standard- of- care’ (soC).
Methods in the public hospital of esine, northern 
italy, 140 consecutive inpatients, with virologically and 
radiographically confirmed COViD-19 admitted in the 
period 5–19 March 2020, were treated with ’soC’ 
(hydroxychloroquine and/or intravenous dexamethasone; 
and/or lopinavir/ritonavir). They were compared with 122 
consecutive inpatients, admitted between 19 March and 
5 april 2020, treated with colchicine (1 mg/day) and soC 
(antiviral drugs were stopped before colchicine, due to 
potential interaction).
results Patients treated with colchicine had a better 
survival rate as compared with soC at 21 days of follow- 
up (84.2% (se=3.3%) vs 63.6% (se=4.1%), p=0.001). 
Cox proportional hazards regression survival analysis 
showed that a lower risk of death was independently 
associated with colchicine treatment (HR=0.151 (95% Ci 
0.062 to 0.368), p<0.0001), whereas older age, worse 
PaO2/FiO2, and higher serum levels of ferritin at entry 
were associated with a higher risk.
Conclusion This proof- of- concept study may support 
the rationale of use of colchicine for the treatment of 
COViD-19. efficacy and safety must be determined in 
controlled clinical trials.
InTrOduCTIOn
Since February 2020, the epidemic of COVID-19 
has severely affected Lombardy, a region in 
Northern Italy, where hospitals were faced with 
the need for quick reorganisation and increased 
demand for critical care.1 This emergency posed 
urgent questions for treatment strategies. The main 
challenge was to understand the natural course of 
the disease, which is triggered by viral infection but 
may evolve into uncontrolled inflammation causing 
lung damage and progression into acute respiratory 
distress syndrome (ARDS). A subgroup of patients 
with severe COVID-19 might have a hyperinflam-
matory syndrome (HIS).2 Based on the assumption 
that a ‘cytokine storm’ drives the progression of the 
disease, the anti- interleukin-6 receptor monoclonal 
antibody tocilizumab has been used in 20 patients 
in China.3 It has been suggested that there may be 
by copyright.
 o
n
 August 8, 2020 at Universita degli Studi di M
ilano. Protected
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217712 on 30 July 2020. Downloaded from
 
2 Scarsi M, et al. Ann Rheum Dis 2020;0:1–4. doi:10.1136/annrheumdis-2020-217712
Treatment
Table 1 Comparison of baseline demographic, clinical and 
laboratory features between patients treated with colchicine plus (+) 
standard- of- care (SoC) or with SoC only
Clinical features
Colchicine
+
soC, n=122 soC, n=140 P value
Male (%) 77 (63) 90 (64) 0.84
Age (years), mean (SD) 69.3 (9.6) 70.5 (13.8) 0.12
Period of observation (days), 
mean (SD)
21.3 (6.8) 25.0 (14.8) 0.012
Smokers or previous smokers (%) 21/96 (22) 18/113 (16) 0.37
Cardiovascular comorbidities* (%) 65/101 (64) 85/115 (74) 0.22
Chronic obstructive 
bronchopneumonia (%)
17/103 (17) 24/111 (22) 0.34
History of malignanicies (%) 9/104 (9) 24/116 (21) 0.013
Ever treated with 
hydroxychloroquine (%)
46/102 (45) 78/138 (57) 0.08
Ever treated with lopinavir/
ritonavir (%)
10/106 (9) 53/139 (38) <0.0001
Ever treated with dexamethasone 
(%)
62/107 (58) 44/139 (32) <0.0001
PaO2/FiO2 (mm Hg/%), mean (SD) 176.6 (81) 244.9 (106) <0.0001
Ferritin (ng/mL), mean (SD) 1987 (1983) 1130 (1104) 0.0005
C reactive protein (mg/L), mean 
(SD)
159.0 (92.9) 112.5 (82.6) 0.0003
Neutrophil count (cell/µL), mean 
(SD)
6859 (4070) 5844 (3786) 0.022
Lymphocyte count (cell/µL), mean 
(SD)
921 (427) 1016 (660) 0.75
*Cardiovascular comorbidities: any history of cardiovascular disease, including 
coronary heart disease (ie, myocardial infarction, angina and coronary 
revascularisation), cerebrovascular disease (ie, stroke and transient ischaemic 
attack) and/or peripheral arterial disease, diabetes mellitus and arterial 
hypertension.
a ‘window of opportunity’ for downmodulating the immune 
response against the virus, without preventing its clearance.4 
In this context, colchicine, an old anti- inflammatory drug, may 
play a role in reverting the disease course of COVID-19.
Colchicine is an alkaloid derived from Colchicum autumnale,5 
currently considered as the first- line treatment for autoinflam-
matory syndromes, such as gout, recurrent pericarditis, familiar 
Mediterranean fever, Behçet’s syndrome and others.6 Colchicine 
inhibits the formation of microtubules, thus affecting a variety 
of cellular processes.7 Microtubule functionality was demon-
strated to be crucial for coronavirus infection and intracellular 
vacuole formation in vitro.8 Colchicine interferes with several 
inflammatory pathways including adhesion and recruitment of 
neutrophils, superoxide production and inflammasome activa-
tion by acting on the cytokine network through the inhibition 
of IL- 1beta.5
The benefits of colchicine were described in different viral- 
mediated inflammatory conditions such as EBV/CMV- induced 
myocarditis,9 pericarditis triggered by influenza B,10 interstitial 
pneumonia of unknown origin11 and interstitial pneumonia 
caused by autoimmune process.12
The side effect profile of colchicine is widely known, with 
gastrointestinal symptoms occurring in up to 17% of patients, 
while severe organ manifestations being rare.13
Based on the identification of HIS in patients with COVID-19 
pneumonia and the anti- inflammatory properties of colchicine, 
we postulated the rationale of use of colchicine in patients 
admitted to the hospital for COVID-19.
MeTHOds
Patients
In the interval between 5 March and 5 April 2020, 272 
patients affected by COVID-19 were admitted to the Valca-
monica Hospital in Esine, Lombardy, Italy. Patients were treated 
according to local guidelines,14 with antiviral drugs, and/
or hydroxychloroquine (HCQ) and/or corticosteroids. This 
protocol will be referred to as ‘standard- of- care’ (SoC). The 
combination of these drugs depended on physician’s indication 
and drug availability. HCQ and lopinavir/ritonavir antiviral 
treatment were not constantly used for intermittent drug avail-
ability due to the emergency. HCQ was given orally 200 mg two 
times per day. Intravenous dexamethasone was administered at 
20 mg/day for 5 days, followed by 10 mg/day for 5 days. Patients 
received antibiotics and supportive care when required.
Since 19 March, colchicine was proposed to the patients as 
off- label treatment, according to the notification provided to 
the local ethics committee. After written informed consent, 
122 consecutive patients were treated with colchicine 1 mg/day 
(reduced to 0.5 mg/day, if severe diarrhoea). In these patients, 
antiviral drugs were stopped because of the potential interaction 
with colchicine.
A control group of 142 patients affected by COVID-19 
pneumonia treated with SoC, admitted before 19 March, was 
retrieved by clinical charts analysis. In two cases, colchicine was 
used as a rescue therapy; these patients were excluded from the 
treatment group and were considered only for the safety anal-
ysis. Eight patients who had a glomerular filtration rate less 
than 30 mL/min were not eligible for colchicine treatment and 
excluded from the study (see online supplementary figure 1).
statistical analysis
Continuous variables were compared by Mann- Whitney test and 
categorical variables by χ2 or Fisher’s exact test.
Survival rates were computed by the Kaplan- Meyer analysis 
and the difference between survival curves by the Mantel- Cox 
(log- rank) test. Survival data were censored at 16 April 2020.
Cox proportional hazards regression survival analysis was 
performed by selecting covariates based on the research ques-
tion (effects of treatment with colchicine) and plausible indepen-
dent variables that were a priori selected among demographical 
(gender and age), clinical and laboratory parameters (PaO2/FiO2 
ratio, ferritin and C reactive protein), comorbidities (history 
of malignancies, cardiovascular disease or chronic obstructive 
pulmonary disease) and other treatments (HCQ, antivirals and 
dexamethasone).
Statistical analysis was performed using GraphPad Prism V.7.0 
and Statview V.5.0.
resulTs
Colchicine was administered to 122 consecutive inpatients 
with COVID-19. The dosage of colchicine was reduced from 
1 to 0.5 mg/day in nine patients (7.4%) due to diarrhoea; no 
other significant adverse events were reported. Survival data 
were compared with those of 140 inpatients admitted before 
the initiation of the protocol with colchicine and treated with 
SoC. SoC patients had more frequently a history of malignancies 
(p=0.013), and of treatment with antiviral drugs (p<0.0001), 
whereas received less frequently corticosteroids (p<0.0001), if 
compared with patients treated with colchicine (plus SoC). On 
the contrary, no difference was observed with regard to sex and 
age between the two groups (table 1). At baseline, serum levels 
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Figure 1 Survival rate in patients treated with colchicine as compared 
with the ’standard- of- care‘ (SoC) group.
Table 2 Univariable and Cox proportional hazards regression analysis of variables associated with survival
Features
univariable analysis Cox proportional hazards regression survival analysis
non- survivors, n=72 survivors, n=190 P value Hr (95% CI) P value
Colchicine treatment (%) 20/72 (28) 102/190 (54) 0.0002 0.151 (0.062 to 0.368) <0.0001
Male (%) 49 (68) 118 (62) 0.37 1.220 (0.586 to 2.543) 0.59
Age (years), mean (SD) 78.4 (7.5) 66.6 (13.4) <0.0001 1.049 (1.007 to 1.093) 0.021
Cardiovascular comorbidities* (%) 46/52 (88) 120/166 (72) 0.017 0.637 (0.211 to 1.920) 0.42
Chronic obstructive bronchopneumonia (%) 11/50 (22) 30/164 (18) 0.56 1.164 (0.519 to 2.611) 0.71
Neoplastic comorbidities (%) 15/52 (29) 18/168 (11) 0.0014 0.549 (0.261 to 1.157) 0.11
Hydroxychloroquine treatment (%) 34/66 (52) 90/174 (52) 0.98 1.359 (0.530 to 3.486) 0.52
Lopinavir/ritonavir treatment (%) 19/67 (28) 44/178 (25) 0.56 1.037 (0.350 to 3.074) 0.94
Dexamethasone treatment (%) 39/67 (58) 68/179 (38) 0.0044 0.870 (0.414 to 1.828) 0.71
PaO2/FiO2 (mm Hg/%), mean (SD) 155.8 (76.7) 229.8 (100.8) 0.50 0.994 (0.990 to 0.998) 0.0048
Ferritin (ng/mL), mean (SD) 1839 (1561) 1450 (1679) 0.50 1.002 (1.001 to 1.004) 0.010
C reactive protein (mg/L), mean (SD) 178.3 (86.7) 121.5 (87.8) 0.16 1.002 (0.998 to 1.006) 0.27
*Cardiovascular comorbidities: any history of cardiovascular disease, including coronary heart disease (ie, myocardial infarction, angina, coronary revascularisation), 
cerebrovascular disease (ie, stroke, transient ischaemic attack) and/or peripheral arterial disease, diabetes mellitus, arterial hypertension.
of C reactive protein and ferritin, as well as neutrophil count, 
were lower, and PaO2/FiO2 ratio was higher in the SoC group 
(table 1).
Up to the 16 April 2020, 20 patients treated with colchi-
cine (16.3%) and 52 patients in the SoC group (37.1%) died 
for complications related to COVID-19 (p<0.001). Kaplan- 
Meyer analysis demonstrated a better survival in the colchicine 
group than in the SoC group (figure 1; log- rank test; p=0.001). 
Survival rate at 21 days of follow- up was estimated to be 84.2% 
(SE=3.3%) in the colchicine group and 63.6% (SE=4.1%) in 
the SoC group (figure 1). Among the colchicine group, there was 
no difference between patients who were treated or not with 
dexamethasone (p=0.37), or with HCQ (p=0.34).
Cox proportional hazards regression survival analysis indi-
cated that a lower risk of death was independently associated 
with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), 
p<0.0001), whereas older age, worse PaO2/FiO2, and higher 
serum levels of ferritin at entry were associated with a higher 
risk (table 2).
dIsCussIOn
To the best of our knowledge, case reports but no case–control 
studies have been published so far about the use of colchicine 
for the treatment of COVID-19.15 This is the first study on a 
large series of consecutive hospitalised patients. The rationale of 
using colchicine resides on both experimental evidence and the 
long- standing experience in the management of autoinflamma-
tory diseases. It is known that colchicine can inhibit the NLRP3 
inflammasome,7 which is activated by the transport of calcium 
ions through the envelope protein of SARS- CoV.16 Moreover, 
there is no evidence that colchicine may worsen the course of a 
disease induced by a virus.17
Practical advantages of the use of such an old anti- inflammatory 
drug are: (1) a well- known safety profile, (2) widespread avail-
ability and (3) low cost. Colchicine was therefore considered as 
a possible valuable treatment option in the context of an unprec-
edented emergency that posed the healthcare system at risk of 
collapse in Lombardy. It soon became clear that many patients 
could rapidly evolve into ARDS, unravelling the insufficient 
resources for ICU and posing dramatic dilemmas in ethics, logis-
tics and therapeutics.1 In the medium- sized Hospital of Esine, 
located in the middle of an alpine valley and serving a popula-
tion of nearly 100 000 adult inhabitants, a treatment protocol 
with colchicine was proposed to consecutive patients admitted 
for COVID-19 as adjunct treatment to the SoC,14 (HCQ—inter-
mittently available, due to national shortage—and/or dexa-
methasone; antiviral drugs—also intermittently available—were 
stopped because of possible interaction with colchicine). We 
can assume that bias selection can be considered as minimal, as 
only patients with formal contraindications to the drug (ie, renal 
failure) were excluded.
The safety profile of colchicine was good, as no patient had to 
stop the drug for severe adverse events. Diarrhoea occurred in 
7.4% of treated patients, which is in line with data reported in 
the systematic review of the literature.13
The main finding of this study was that patients treated with 
colchicine had a better survival rate as compared with SoC. We 
acknowledge that this result might be affected by a survival bias 
deriving from the inclusion in the colchicine group of patients 
who were ‘survivors’ at the moment of initiating the treatment 
with this drug. However, this bias is likely to be minimal, since 
the interval between hospital admission and colchicine initiation 
was very short in most cases (mean of 1 day), and mortality in the 
first days after admission was anyway limited (figure 1). Baseline 
differences between patients treated with colchicine and SoC 
must be acknowledged: patients in the SoC group were older 
and received less frequently corticosteroids. However, these 
patients received more often other treatments (HCQ and antivi-
rals) and seemed to suffer from a less severe disease (better PaO2/
by copyright.
 o
n
 August 8, 2020 at Universita degli Studi di M
ilano. Protected
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217712 on 30 July 2020. Downloaded from
 
4 Scarsi M, et al. Ann Rheum Dis 2020;0:1–4. doi:10.1136/annrheumdis-2020-217712
Treatment
FiO2, lower CRP, ferritin and neutrophil count). Indeed, Cox 
proportional hazards regression survival analysis showed the 
independent association of colchicine treatment with survival 
and that of older age, higher serum levels of ferritin and more 
severe hypoxaemia at admission with death.
In conclusion, our report can be considered as a proof- of- 
concept study supporting the possible use of colchicine in the 
treatment of the early phase of COVID-19 with the purpose 
of preventing the host’s autoinflammatory response. Properly 
designed trials will determine the efficacy and safety of colchi-
cine and the best protocol in terms of dosage and timing of 
administration in patients with COVID-19. Such trials have been 
approved in Greece,18 Italy19 and Canada.20
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